BMO Capital Initiates Coverage On ACADIA Pharmaceuticals With Outperform Rating, Announces Price Target of $31
BMO Capital Initiates Coverage On ACADIA Pharmaceuticals With Outperform Rating, Announces Price Target of $31
BMO資本開始對阿卡迪亞藥業進行覆蓋，給予超越市場評級，並宣佈價格目標爲31美元。
BMO Capital analyst Keith Tapper initiates coverage on ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform rating and announces Price Target of $31.
BMO資本分析師Keith Tapper開始對阿卡迪亞製藥（納斯達克股票代碼：ACAD）進行覆蓋，給出跑贏大盤的評級並宣佈價格目標爲31美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。